2024-11-14T08:42:37-05:00 2023-12-31 522436535 COMER & COMPANY CPA'S LLC 61 MAIN STREET MIDDLETOWN CT 064573408 990EZ 2023-01-01 461995761 INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY FOUNDATION INTE 2126395999 PO BOX 810 NEW YORK NY 10021 JOACHIM YAHALOM MD CHAIRMAN 2126395999 2024-10-30 true false THOMAS D COMER CPA P00129178 8603462100 2024-10-30 2023 2024-10-15 13:58:12Z X WWW.ILROG.COM X X 84312 X 84185 127 84312 35788 1450 39761 76999 7313 147658 154971 147658 154971 147658 154971 147658 154971 X THE MISSION OF ILROG IS TO IMPROVE THE OUTCOME FOR PATIENTS BY ENCOURAGING THE APPROPRIATE INTEGRATION OF RADIATION THERAPY IN THE MANAGEMENT OF LYMPHOMA. ILROG OBJECTIVES: - TO OPTIMIZE, ADVANCE AND HARMONIZE THE INTEGRATION OF RADIATION THERAPY IN THE MANAGEMENT OF LYMPHOMA PATIENTS. - TO INFORM THE HEMATOLOGY, MEDICAL AND RADIATION ONCOLOGY COMMUNITIES OF THE LYMPHOMA SCENARIOS WHERE APPROPRIATE UTILIZATION OF RADIOTHERAPY IS ADVANTAGEOUS. - TO DEVELOP AND DISSEMINATE EVIDENCE-BASED GUIDELINES FOR RADIOTHERAPY FIELDS, DOSES AND TECHNIQUES FOR ALL TYPES OF LYMPHOMAS. - TO TRAIN RADIATION ONCOLOGISTS WORLDWIDE IN USING MODERN LYMPHOMA RADIOTHERAPY PRINCIPLES AND TECHNIQUES VIA COLLABORATION WITH APPROPRIATE NATIONAL OR REGIONAL SCIENTIFIC SOCIETIES. - TO PROVIDE A WORLDWIDE FORUM FOR RADIATION ONCOLOGISTS WHO TREAT LYMPHOMAS TO DISCUSS AND SHARE INFORMATION AND IDEAS. - TO PROVIDE A SOURCE OF INFORMATION FOR LYMPHOMA PATIENTS EXPLAINING THE ADVANTAGES AND RISKS ASSOCIATED WITH RADIATI 2023 ACCOMPLISHMENTS INCLUDE CONDUCTING AND PUBLISHING RESEARCH IN NEW THERAPIES FOR LYMPHOMA AND MULTIPLE MYELOMA, INCLUDING CAR T CELL. EDUCATIONAL CONFERENCES IN MANCHESTER AND LONDON, UK, AND LYON, FRANCE. CONTINUED EDUCATON OF MEMBERSHIP BY CREATING, PUBLISHING AND CREATING GUIDELINES. 74199 74199 JOACHIM YAHALOM MD CHAIRMAN 12.00 0 LENA SPECHT MD VICE-CHAIRMA 8.00 0 TIM ILLIDGE MD SECRETARY/TR 8.00 0 false false false false false false false false false INTERNATIONAL LYMPHOMA RADIATION INTERNATIONAL LYMPHOMA RADIATION 351 E 51ST ST APT 14C 35 E 51ST ST APT 14C NEW YORK NY 10022 2126395999 false false false false false false false false false false false NONE NONE true X 34698 52029 31583 35058 44185 197553 34698 52029 31583 35058 44185 197553 197553 443 184 127 754 443 184 127 754 35141 52213 31583 35058 44312 198307 0.99620 0.99520 0.00000 0.00000 X SUPPORTING SCHEDULE RESEARCH 40,000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED FORM 990-EZ, PART I, LINE 16 EXPENSES OFFICE EXPENSES 187 WEBSITE/HOSTING 1,818 TECHNOLOGY EXPENSES 2,492 CONFERENCES & MEETINGS 33,524 BANK FEES 91 PAYROLL PROCESSING FEES 755 DUES & SUBSCRIPTIONS 504 STEERING COMMITTEE EXP 390 TOTAL 39,761 FORM 990-EZ, PART III THE MISSION OF ILROG IS TO IMPROVE THE OUTCOME FOR PATIENTS BY ENCOURAGING THE APPROPRIATE INTEGRATION OF RADIATION THERAPY IN THE MANAGEMENT OF LYMPHOMA. ILROG OBJECTIVES: - TO OPTIMIZE, ADVANCE AND HARMONIZE THE INTEGRATION OF RADIATION THERAPY IN THE MANAGEMENT OF LYMPHOMA PATIENTS. - TO INFORM THE HEMATOLOGY, MEDICAL AND RADIATION ONCOLOGY COMMUNITIES OF THE LYMPHOMA SCENARIOS WHERE APPROPRIATE UTILIZATION OF RADIOTHERAPY IS ADVANTAGEOUS. - TO DEVELOP AND DISSEMINATE EVIDENCE-BASED GUIDELINES FOR RADIOTHERAPY FIELDS, DOSES AND TECHNIQUES FOR ALL TYPES OF LYMPHOMAS. - TO TRAIN RADIATION ONCOLOGISTS WORLDWIDE IN USING MODERN LYMPHOMA RADIOTHERAPY PRINCIPLES AND TECHNIQUES VIA COLLABORATION WITH APPROPRIATE NATIONAL OR REGIONAL SCIENTIFIC SOCIETIES. - TO PROVIDE A WORLDWIDE FORUM FOR RADIATION ONCOLOGISTS WHO TREAT LYMPHOMAS TO DISCUSS AND SHARE INFORMATION AND IDEAS. - TO PROVIDE A SOURCE OF INFORMATION FOR LYMPHOMA PATIENTS EXPLAINING THE ADVANTAGES AND RISKS ASSOCIATED WITH RADIATION THERAPY. - TO INITIATE, SUPPORT AND CONDUCT RESEARCH THAT WILL FURTHER THE UNDERSTANDING OF RADIOTHERAPY IN THE TREATMENT OF LYMPHOMA AND THAT WILL IMPROVE THE THERAPEUTIC RATIO OF USING RADIOTHERAPY ALONE OR IN COMBINATION WITH OTHER THERAPIES. FORM 990-EZ, PART III, LINE 28 2023 ACCOMPLISHMENTS INCLUDE CONDUCTING AND PUBLISHING RESEARCH IN NEW THERAPIES FOR LYMPHOMA AND MULTIPLE MYELOMA, INCLUDING CAR T CELL. EDUCATIONAL CONFERENCES IN MANCHESTER AND LONDON, UK, AND LYON, FRANCE. CONTINUED EDUCATON OF MEMBERSHIP BY CREATING, PUBLISHING AND CREATING GUIDELINES.